RareWays is a research directory. It helps you understand the science. It is not medical advice. Always discuss your care options with your healthcare team.
Coverage: 2020-01-01 onwards, with up to 300 results per query from PubMed and Europe PMC and separate limits on other sources. This is a selected index, not a complete literature search.
Updates are delayed or unverified. Check original sources for the latest information.
Your saved research and appointment questionsView recorded trial and retraction changes
Medullary Thyroid Carcinoma: Research Summary
Printed from RareWays (rareways.org)
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Health-Related Quality of Life in Medullary Thyroid Carcinoma: A Multicenter Canadian Cross-sectional Survey and Retrospective Cohort Study
Gabriela Szuman et al., Canadian Journal of Diabetes (14 October 2026)
https://doi.org/10.1016/j.jcjd.2026.08.174
- 2.
Contemporary systemic therapy of medullary thyroid cancer.
Abdel-Rahman Omar, Expert opinion on pharmacotherapy (14 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42872471/
- 3.
Tumor growth in medullary thyroid microcarcinoma during delayed surgery: a single-center study
Yuanmeng Li et al., BMC Endocrine Disorders (5 October 2026)
https://doi.org/10.1186/s12902-026-02606-2
- 4.
Identification of RET PROTAC with excellent degradation efficiency against medullary thyroid carcinoma.
Song Jaewon et al., European journal of medicinal chemistry (5 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42161102/
- 5.
Towards risk-adapted surgical de-escalation in sporadic medullary thyroid carcinoma: integrating desmoplastic stromal reaction, nodal status, and multifocality
Francesco Pennestrì et al., Surgery (1 October 2026)
https://doi.org/10.1016/j.surg.2026.110732
Clinical Trials : Australian Sites
Ask your doctor whether you or your child may be eligible for any of these trials. Each has its ID and full eligibility criteria at the link shown.
- 1.
A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
NCT04211337 · Active (not recruiting) · Phase 3 · Loxo Oncology, Inc.
Ages 12 and over
https://clinicaltrials.gov/study/NCT04211337
- 2.
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors
NCT03899792 · Active (not recruiting) · Phase 1 / Phase 2 · Eli Lilly and Company
Ages 6 Months to 21
https://clinicaltrials.gov/study/NCT03899792
- 3.
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
NCT03157128 · Active (not recruiting) · Phase 1 / Phase 2 · Eli Lilly and Company
Ages 12 and over
https://clinicaltrials.gov/study/NCT03157128
- 4.
A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer
NCT01896479 · Active (not recruiting) · Phase 4 · Exelixis
Ages 18 and over
https://clinicaltrials.gov/study/NCT01896479
- 5.
Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment
NCT01298323 · Completed · Phase 3 · Sanofi
Ages 18 and over
https://clinicaltrials.gov/study/NCT01298323
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Medullary Thyroid Carcinoma
Medullary thyroid carcinoma is a rare cancer that starts in the C cells of the thyroid gland, which make the hormone calcitonin. It can occur by chance or run in families, often because of changes in the RET gene. Treatment is mainly surgery to remove the thyroid, and targeted medicines may be used for advanced disease.
This overview is general information, not an individual medical assessment. Research is selected automatically and may include mismatches. How we select and explain research.
Most Recent Research
Common Questions
What is Medullary Thyroid Carcinoma?
Medullary thyroid carcinoma is a rare cancer that starts in the C cells of the thyroid gland, which make the hormone calcitonin. It can occur by chance or run in families, often because of changes in the RET gene. Treatment is mainly surgery to remove the thyroid, and targeted medicines may be used for advanced disease.
How many clinical trials are available for Medullary Thyroid Carcinoma?
RareWays currently indexes 66 clinical trials for Medullary Thyroid Carcinoma, of which 8 are actively recruiting. These counts cover indexed trials across countries, not just your country. An Australian site does not necessarily mean that site is recruiting. Check locations, eligibility and current availability with the study team.
Where does the research data for Medullary Thyroid Carcinoma come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is refreshed automatically every day. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Medullary Thyroid Carcinoma.
Your email and selected disease are stored for these updates. Unsubscribe any time. Privacy and deletion.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.